Next Article in Journal
Hypoxia and Hypoxia-Inducible Factor Signaling in Muscular Dystrophies: Cause and Consequences
Next Article in Special Issue
Identification of SCN5a p.C335R Variant in a Large Family with Dilated Cardiomyopathy and Conduction Disease
Previous Article in Journal
Metabolite Profiling and Transcriptome Analysis Provide Insight into Seed Coat Color in Brassica juncea
Previous Article in Special Issue
CMR-Based Risk Stratification of Sudden Cardiac Death and Use of Implantable Cardioverter–Defibrillator in Non-Ischemic Cardiomyopathy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 13
10.3390/ijms22137218
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Pushing the Limits of Medical Management in HCM: A Review of Current Pharmacological Therapy Options

by
Cristian Stătescu
1,2,
Ștefana Enachi
1,*,
Carina Ureche
1,2,
Laura Țăpoi
1,
Larisa Anghel
1,2,
Delia Șalaru
1,2,
Carmen Pleșoianu
1,2,
Mădălina Bostan
1,2,
Dragoș Marcu
1,2,
Mircea Ovanez Balasanian
1,2 and
Radu Andy Sascău
1,2
1
Cardiology Department, Cardiovascular Diseases Institute “Prof. Dr. George I.M. Georgescu”, Carol I Boulevard No. 50, 700503 Iași, Romania
2
Internal Medicine Department, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(13), 7218; https://doi.org/10.3390/ijms22137218
Submission received: 31 May 2021 / Revised: 27 June 2021 / Accepted: 29 June 2021 / Published: 5 July 2021
(This article belongs to the Special Issue Recent Advancements in Primary Cardiomyopathies)
Browse Figures
Versions Notes

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common monogenic cardiac disease with a highly variable phenotypic expression, ranging from asymptomatic to drug refractory heart failure (HF) presentation. Pharmacological therapy is the first line of treatment, but options are currently limited to nonspecific medication like betablockers or calcium channel inhibitors, with frequent suboptimal results. While being the gold standard practice for the management of drug refractory HCM patients, septal reduction therapy (SRT) remains an invasive procedure with associated surgical risks and it requires the expertise of the operating centre, thus limiting its accessibility. It is therefore with high interest that researchers look for pharmacological alternatives that could provide higher rates of success. With new data gathering these past years as well as the development of a new drug class showing promising results, this review provides an up-to-date focused synthesis of existing medical treatment options and future directions for HCM pharmacological treatment.
Keywords: hypertrophic cardiomyopathy; pharmacotherapy; drug trials; myosin inhibitors; mavacamten hypertrophic cardiomyopathy; pharmacotherapy; drug trials; myosin inhibitors; mavacamten

Share and Cite

MDPI and ACS Style

Stătescu, C.; Enachi, Ș.; Ureche, C.; Țăpoi, L.; Anghel, L.; Șalaru, D.; Pleșoianu, C.; Bostan, M.; Marcu, D.; Ovanez Balasanian, M.; et al. Pushing the Limits of Medical Management in HCM: A Review of Current Pharmacological Therapy Options. Int. J. Mol. Sci. 2021, 22, 7218. https://doi.org/10.3390/ijms22137218

AMA Style

Stătescu C, Enachi Ș, Ureche C, Țăpoi L, Anghel L, Șalaru D, Pleșoianu C, Bostan M, Marcu D, Ovanez Balasanian M, et al. Pushing the Limits of Medical Management in HCM: A Review of Current Pharmacological Therapy Options. International Journal of Molecular Sciences. 2021; 22(13):7218. https://doi.org/10.3390/ijms22137218

Chicago/Turabian Style

Stătescu, Cristian, Ștefana Enachi, Carina Ureche, Laura Țăpoi, Larisa Anghel, Delia Șalaru, Carmen Pleșoianu, Mădălina Bostan, Dragoș Marcu, Mircea Ovanez Balasanian, and et al. 2021. "Pushing the Limits of Medical Management in HCM: A Review of Current Pharmacological Therapy Options" International Journal of Molecular Sciences 22, no. 13: 7218. https://doi.org/10.3390/ijms22137218

APA Style

Stătescu, C., Enachi, Ș., Ureche, C., Țăpoi, L., Anghel, L., Șalaru, D., Pleșoianu, C., Bostan, M., Marcu, D., Ovanez Balasanian, M., & Sascău, R. A. (2021). Pushing the Limits of Medical Management in HCM: A Review of Current Pharmacological Therapy Options. International Journal of Molecular Sciences, 22(13), 7218. https://doi.org/10.3390/ijms22137218

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop